Home Featured Page 85

Featured

Latest

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving...

BetterLife Pharma to Host Investors Update Call on September 18, 2023

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global...

Does Humanity’s Fate Lie in the Hands of the Fungal Kingdom?

PT441 – The American Psychedelic Practitioners Association and the Mission to...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for...

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of...

Psychedelic Research Bulletin: July and August 2023

PT440 – Coming Back to Stillness, Microdosing and Adaptogens, and What...

EDITOR PICKS

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect

The Psychedelic Practitioner Issue 5: Groups in Practice

Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering

Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving...

BetterLife Pharma to Host Investors Update Call on September 18, 2023

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global...

Does Humanity’s Fate Lie in the Hands of the Fungal Kingdom?

PT441 – The American Psychedelic Practitioners Association and the Mission to...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for...

BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of...

Psychedelic Research Bulletin: July and August 2023

PT440 – Coming Back to Stillness, Microdosing and Adaptogens, and What...

EDITOR PICKS

‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase...

Psychedelic Policy Briefing: Week of June 22nd, 2026

Mike Finoia – The Comedy of Conscious Aging, Episode 16

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY